Nplate: A Game-Changer in Chemotherapy-Induced Thrombocytopenia
Amgen's Nplate proves highly effective in preventing thrombocytopenia from chemotherapy, enabling full-dose cancer treatment without reduction. In patients with various cancers, 84% on Nplate maintained chemotherapy doses, unlike only 36% with a placebo. Such findings could revolutionize practice standards for oncologists worldwide.
Amgen's innovative drug Nplate has demonstrated remarkable efficacy in combatting chemotherapy-induced thrombocytopenia, a newsworthy breakthrough reported ahead of the American Society of Clinical Oncology's meeting in Chicago. The condition, an abnormally low blood platelet count, poses significant risks for cancer patients, including severe internal bleeding.
The pivotal trial involved 165 patients suffering from colorectal, gastroesophageal, or pancreatic cancer, each undergoing chemotherapy known to cause thrombocytopenia. Those receiving the subcutaneous injection of Nplate showed a dramatic reduction in chemotherapy dose reductions due to low platelet issues.
Dr. Hanny Al-Samkari emphasizes the potential practice-changing implications of these findings, particularly since no FDA-approved treatments currently exist for this condition. As the study reveals, Nplate enables continued full-strength chemotherapy, potentially improving patient survival rates. This advancement marks a significant milestone in oncology treatment.
(With inputs from agencies.)
- READ MORE ON:
- Nplate
- chemotherapy
- thrombocytopenia
- cancer
- ASCO
- Amgen
- oncology
- platelet
- romiplostim
- clinical trial
Google News